Abstract
BackgroundChimeric antigen receptor (CAR) T cell therapy has proven highly effective in the treatment of hematologic malignancies, however multiple barriers in the tumor microenvironment (TME) reduce its efficacy against solid...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
